PTEN and cancer: As docetaxel is the gold standard first line treatment for hormone-refractory prostate tumors, the authors observed that single treatment with the anti-microtubule agent improved tumor reduction marginally in PTEN null cancers, confirming data from clinical trials [76]; if docetaxel is coupled with a specific JAK inhibitor, a dramatic shrinkage of the tumor was observed, as a consequence of the reprogrammed cancer phenotype to an inflamed tumor, with reduction of immune suppressive cytokines and accumulation of pro-inflamed stromal cells in the tumor microenvironment.